This invention concerns the use of a compound of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo C1-6alkyl C1-6 alkylcarbonyl C1-6alkyloxycarbonyl aminocarbonyl C1-6alkyl substituted with hydroxy, carboxyl, cyano, amino, amino substituted with piperidinyl, amino substituted with C1-4alkyl substituted piperidinyl, mono -or di(C1-6alkyl)amino, aminocarbonyl, mono -or di(C1-6alkyl)aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkyloxy, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl polyhaloC1-4alkyl cyano amino mono -or di(C1-6alkyl)aminocarbonyl C1-6alkyloxycarbonyl C1-6alkylcarbonyloxy aminoS(=O)2- mono -or di(C1-6alkyl)aminoS(=O)2 -C(=N-Rx)NRyRz Q is optionally substituted C3-6cycloalkyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl, or Q is a radical of formula (b-1), (b-2), or (b-3), L is optionally substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle aryl is optionally substituted phenyl for the manufacture of a medicament for the prevention or the treatment of inflammatory and/or auto-immune diseases mediated through TNF-α and/or IL-12.Linvention concerne lutilisation dun composé de formule (I), dun N-oxyde, dun sel daddition acceptable sur le plan pharmaceutique, dune amine quaternaire et dune forme isomère sur le plan stéréochimique de celui-ci. Dans cette formule, Z désigne un halo un alkyle en C1-6 un alkylcarbonyle en C1-6 un alkyloxycarbonyle en C1-6 un aminocarbonyle un alkyle en C1-6 substitué par un hydroxy, un carboxyle, un cyano, un amino, un amino substitué par un pipéridinyle, un amino substitué par un pipéridinyle substitué par un alykle en C1-4, un mono -ou di(C1-6alkyl)amino, un aminocarbonyle, un mono -ou di(C1-6alkyl)aminocarbonyle, un
